Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
14.05
+0.26 (1.89%)
At close: Mar 19, 2026, 4:00 PM EDT
14.05
0.00 (0.00%)
After-hours: Mar 19, 2026, 4:02 PM EDT
Amylyx Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts that cover Amylyx Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $20.11, which forecasts a 43.13% increase in the stock price over the next year. The lowest target is $8.00 and the highest is $34.
Price Target: $20.11 (+43.13%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Amylyx Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 6 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 8 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $25 → $30 | Strong Buy | Maintains | $25 → $30 | +113.52% | Mar 19, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $28 → $34 | Strong Buy | Maintains | $28 → $34 | +141.99% | Mar 4, 2026 |
| Stifel | Stifel | Strong Buy Initiates $21 | Strong Buy | Initiates | $21 | +49.47% | Mar 3, 2026 |
| B of A Securities | B of A Securities | Strong Buy Maintains $15 → $19 | Strong Buy | Maintains | $15 → $19 | +35.23% | Feb 20, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $28 | Strong Buy | Maintains | $20 → $28 | +99.29% | Feb 10, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
44.60M
EPS This Year
-1.39
from -1.53
EPS Next Year
-1.42
from -1.39
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | 132.0M | |||
| Avg | n/a | 44.6M | |||
| Low | n/a | 2.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.84 | -0.95 | |||
| Avg | -1.39 | -1.42 | |||
| Low | -1.61 | -1.56 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.